Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Tankyrase is necessary for canonical Wnt signaling during kidney development.

Karner CM, Merkel CE, Dodge M, Ma Z, Lu J, Chen C, Lum L, Carroll TJ.

Dev Dyn. 2010 Jul;239(7):2014-23. doi: 10.1002/dvdy.22340.

2.

PARsing the phrase "all in for Axin"- Wnt pathway targets in cancer.

Fearon ER.

Cancer Cell. 2009 Nov 6;16(5):366-8. doi: 10.1016/j.ccr.2009.10.007. Review.

3.

Tankyrase inhibitors as therapeutic targets for cancer.

Kamal A, Riyaz S, Srivastava AK, Rahim A.

Curr Top Med Chem. 2014;14(17):1967-76. Review.

PMID:
25262803
4.

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.

Riffell JL, Lord CJ, Ashworth A.

Nat Rev Drug Discov. 2012 Dec;11(12):923-36. doi: 10.1038/nrd3868. Review.

PMID:
23197039
5.

Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.

Lakshmi TV, Bale S, Khurana A, Godugu C.

Curr Drug Targets. 2017;18(10):1214-1224. doi: 10.2174/1389450117666160715152503. Review.

PMID:
27425647
6.

Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.

Ferri M, Liscio P, Carotti A, Asciutti S, Sardella R, Macchiarulo A, Camaioni E.

Eur J Med Chem. 2017 Dec 15;142:506-522. doi: 10.1016/j.ejmech.2017.09.030. Epub 2017 Oct 7. Review.

PMID:
29107427
7.

Targeting Tankyrase to Fight WNT-dependent Tumours.

Thorvaldsen TE.

Basic Clin Pharmacol Toxicol. 2017 Aug;121(2):81-88. doi: 10.1111/bcpt.12786. Epub 2017 May 10. Review.

PMID:
28371398
8.

The telomeric PARP, tankyrases, as targets for cancer therapy.

Seimiya H.

Br J Cancer. 2006 Feb 13;94(3):341-5. Review.

9.

Tankyrases as drug targets.

Lehtiö L, Chi NW, Krauss S.

FEBS J. 2013 Aug;280(15):3576-93. doi: 10.1111/febs.12320. Epub 2013 Jun 18. Review.

10.

Recent advances in the structure-based rational design of TNKSIs.

Zhan P, Song Y, Itoh Y, Suzuki T, Liu X.

Mol Biosyst. 2014 Nov;10(11):2783-99. doi: 10.1039/c4mb00385c. Review.

PMID:
25211064
11.

WNT/beta-catenin signaling in nephron progenitors and their epithelial progeny.

Schmidt-Ott KM, Barasch J.

Kidney Int. 2008 Oct;74(8):1004-8. doi: 10.1038/ki.2008.322. Epub 2008 Jul 16. Review.

12.

Wnt/beta-catenin signaling: components, mechanisms, and diseases.

MacDonald BT, Tamai K, He X.

Dev Cell. 2009 Jul;17(1):9-26. doi: 10.1016/j.devcel.2009.06.016. Review.

13.

Tankyrases: structure, function and therapeutic implications in cancer.

Haikarainen T, Krauss S, Lehtio L.

Curr Pharm Des. 2014;20(41):6472-88. Review.

14.

Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.

Mariotti L, Pollock K, Guettler S.

Br J Pharmacol. 2017 Dec;174(24):4611-4636. doi: 10.1111/bph.14038. Epub 2017 Nov 5. Review.

15.

Cystic kidney disease: the role of Wnt signaling.

Lancaster MA, Gleeson JG.

Trends Mol Med. 2010 Aug;16(8):349-60. doi: 10.1016/j.molmed.2010.05.004. Epub 2010 Jun 22. Review.

16.

Molecular regulation of kidney development: is the answer blowing in the Wnt?

Merkel CE, Karner CM, Carroll TJ.

Pediatr Nephrol. 2007 Nov;22(11):1825-38. Epub 2007 Jun 7. Review.

PMID:
17554566
17.

Wnt signaling in kidney tubulointerstitium during disease.

Maarouf OH, Ikeda Y, Humphreys BD.

Histol Histopathol. 2015 Feb;30(2):163-71. doi: 10.14670/HH-30.163. Epub 2014 Oct 9. Review.

PMID:
25297005

Supplemental Content

Support Center